Biodesix (BDSX) EBIAT (2019 - 2025)
Biodesix (BDSX) has disclosed EBIAT for 7 consecutive years, with -$4.0 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, EBIAT rose 51.76% year-over-year to -$4.0 million, compared with a TTM value of -$35.3 million through Dec 2025, up 17.86%, and an annual FY2025 reading of -$35.3 million, up 17.86% over the prior year.
- EBIAT was -$4.0 million for Q4 2025 at Biodesix, up from -$8.7 million in the prior quarter.
- Across five years, EBIAT topped out at -$4.0 million in Q4 2025 and bottomed at -$20.3 million in Q4 2022.
- Average EBIAT over 5 years is -$11.9 million, with a median of -$11.4 million recorded in 2021.
- The sharpest move saw EBIAT skyrocketed 65.62% in 2021, then plummeted 123.9% in 2022.
- Year by year, EBIAT stood at -$13.3 million in 2021, then tumbled by 53.12% to -$20.3 million in 2022, then skyrocketed by 55.29% to -$9.1 million in 2023, then grew by 9.26% to -$8.3 million in 2024, then soared by 51.76% to -$4.0 million in 2025.
- Business Quant data shows EBIAT for BDSX at -$4.0 million in Q4 2025, -$8.7 million in Q3 2025, and -$11.5 million in Q2 2025.